N-Phenylacetyl-L-prolylglycine ethyl ester
|Other names||N-Phenylacetyl-l-prolylglycine ethyl ester; GVS-111|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||318.367 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
N-Phenylacetyl-l-prolylglycine ethyl ester is promoted as a nootropic and is a prodrug of cycloprolylglycine. Other names include the brand name Noopept (Russian: Ноопепт), developmental code GVS-111; proposed INN omberacetam.
Its synthesis was first reported in 1996. It is orally available, and as of 2017 its metabolism and elimination half-life were not well understood, as cycloprolylglycine had not been measured in humans following administration.
As of 2017 there had been many studies conducted in cells and in animal models, and there had been one clinical trial with 41 subjects, which compared Noopept and piracetam in people with traumatic brain injury.